| Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer A Harrod, J Fulton, VTM Nguyen, M Periyasamy, L Ramos-Garcia, CF Lai, ... Oncogene 36 (16), 2286-2296, 2017 | 190 | 2017 |
| Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion VTM Nguyen, I Barozzi, M Faronato, Y Lombardo, JH Steel, N Patel, ... Nature communications 6 (1), 10044, 2015 | 147 | 2015 |
| APOBEC3B-mediated cytidine deamination is required for estrogen receptor action in breast cancer M Periyasamy, H Patel, CF Lai, VTM Nguyen, E Nevedomskaya, A Harrod, ... Cell reports 13 (1), 108-121, 2015 | 132 | 2015 |
| TGF-β induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression S Ottaviani, J Stebbing, AE Frampton, S Zagorac, J Krell, A de Giorgio, ... Nature communications 9 (1), 1845, 2018 | 127 | 2018 |
| The pioneer factor PBX1 is a novel driver of metastatic progression in ERα-positive breast cancer L Magnani, DK Patten, VTM Nguyen, SP Hong, JH Steel, N Patel, ... Oncotarget 6 (26), 21878, 2015 | 64 | 2015 |
| DMXL2 drives epithelial to mesenchymal transition in hormonal therapy resistant breast cancer through Notch hyper-activation M Faronato, VTM Nguyen, DK Patten, Y Lombardo, JH Steel, N Patel, ... Oncotarget 6 (26), 22467, 2015 | 42 | 2015 |
| LMTK3 represses tumor suppressor-like genes through chromatin remodeling in breast cancer Y Xu, H Zhang, N Angelopoulos, J Nunes, A Reid, L Buluwela, L Magnani, ... Cell reports 12 (5), 837-849, 2015 | 33 | 2015 |
| Selective inhibition of CDK9 in triple negative breast cancer EH Mustafa, G Laven-Law, Z Kikhtyak, V Nguyen, S Ali, AA Pace, R Iggo, ... Oncogene 43 (3), 202-215, 2024 | 8 | 2024 |
| AKT and EZH2 inhibitors kill TNBCs by hijacking mechanisms of involution AE Schade, N Perurena, Y Yang, CL Rodriguez, A Krishnan, A Gardner, ... Nature 635 (8039), 755-763, 2024 | 3 | 2024 |
| Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer C Gemma, CF Lai, AK Singh, A Belfiore, N Portman, HZ Milioli, ... Cancer research 84 (24), 4283-4297, 2024 | 1 | 2024 |
| Epigenetic and Oncogenic Inhibitors Cooperatively Drive Differentiation and Kill KRAS-Mutant Colorectal Cancers P Loi, AE Schade, CL Rodriguez, A Krishnan, N Perurena, VTM Nguyen, ... Cancer Discovery 14 (12), 2430-2449, 2024 | | 2024 |
| Understanding the mechanism of action of transcriptional inhibitors in breast cancer TMV Nguyen Imperial College London, 2020 | | 2020 |
| TGF-ß induces miR-100 and miR-125b but blocks let-7a through LIN28B controlling PDAC progression. S Ottaviani, J Stebbing, AE Frampton, S Zagorac, J Krell, A de Giorgio, ... University of Sussex, 0 | | |
